Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache

Research output: Contribution to journalArticle

Abstract

Myofascial pain syndrome (MPS) is characterised by acute and specific pain affecting the piriformis, iliopsoas or scalenus anterior muscles. Tension-type headache (TH) is a common pathological condition, which can be chronic or episodic. Based on its muscle-relaxant properties, botulinum toxin type A (BTX-A) has demonstrated efficacy in a variety of conditions involving dysregulated muscle contractions. Patients with MPS (n = 40) or TH (n = 20) were recruited to two randomised, single-blind studies, respectively. Each patient received either BTX-A or methylprednisolone, injected into the affected muscles after administration of a local anaesthetic. Pain was assessed at baseline, and 30 and 60 days post-treatment using a standard visual analogue scale. At 30 days post-injection, the mean pain score in all treatment groups was reduced compared with baseline in both studies, although the difference between treatment groups was not significant at this time in either study. However, by 60 days post-injection, the mean pain score has continued to fall in the BTX-A treatment groups, compared with a waning of the steroid therapeutic activity in the controls. The net effect was a highly significant difference between the two treatments in both the MPS (P <0.0001) and TH (P <0.0005) studies. No major adverse events were reported. In conclusion, BTX-A produces a more prolonged pain relief than methylprednisolone in patients suffering from MPS or TH.

Original languageEnglish
JournalEuropean Journal of Neurology
Volume6
Issue numberSUPPL. 4
Publication statusPublished - 1999

Fingerprint

Myofascial Pain Syndromes
Tension-Type Headache
Type A Botulinum Toxins
Injections
Headache
Pain
Methylprednisolone
Muscles
Therapeutics
Single-Blind Method
Acute Pain
Muscle Contraction
Local Anesthetics
Visual Analog Scale
Steroids

Keywords

  • Botulinum toxin
  • Muscle relaxant
  • Myofascial pain syndrome
  • Pain
  • Tension-type headache

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache. / Porta, Mauro.

In: European Journal of Neurology, Vol. 6, No. SUPPL. 4, 1999.

Research output: Contribution to journalArticle

@article{0260fadd7ce54714baa369bdc7f93132,
title = "Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache",
abstract = "Myofascial pain syndrome (MPS) is characterised by acute and specific pain affecting the piriformis, iliopsoas or scalenus anterior muscles. Tension-type headache (TH) is a common pathological condition, which can be chronic or episodic. Based on its muscle-relaxant properties, botulinum toxin type A (BTX-A) has demonstrated efficacy in a variety of conditions involving dysregulated muscle contractions. Patients with MPS (n = 40) or TH (n = 20) were recruited to two randomised, single-blind studies, respectively. Each patient received either BTX-A or methylprednisolone, injected into the affected muscles after administration of a local anaesthetic. Pain was assessed at baseline, and 30 and 60 days post-treatment using a standard visual analogue scale. At 30 days post-injection, the mean pain score in all treatment groups was reduced compared with baseline in both studies, although the difference between treatment groups was not significant at this time in either study. However, by 60 days post-injection, the mean pain score has continued to fall in the BTX-A treatment groups, compared with a waning of the steroid therapeutic activity in the controls. The net effect was a highly significant difference between the two treatments in both the MPS (P <0.0001) and TH (P <0.0005) studies. No major adverse events were reported. In conclusion, BTX-A produces a more prolonged pain relief than methylprednisolone in patients suffering from MPS or TH.",
keywords = "Botulinum toxin, Muscle relaxant, Myofascial pain syndrome, Pain, Tension-type headache",
author = "Mauro Porta",
year = "1999",
language = "English",
volume = "6",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache

AU - Porta, Mauro

PY - 1999

Y1 - 1999

N2 - Myofascial pain syndrome (MPS) is characterised by acute and specific pain affecting the piriformis, iliopsoas or scalenus anterior muscles. Tension-type headache (TH) is a common pathological condition, which can be chronic or episodic. Based on its muscle-relaxant properties, botulinum toxin type A (BTX-A) has demonstrated efficacy in a variety of conditions involving dysregulated muscle contractions. Patients with MPS (n = 40) or TH (n = 20) were recruited to two randomised, single-blind studies, respectively. Each patient received either BTX-A or methylprednisolone, injected into the affected muscles after administration of a local anaesthetic. Pain was assessed at baseline, and 30 and 60 days post-treatment using a standard visual analogue scale. At 30 days post-injection, the mean pain score in all treatment groups was reduced compared with baseline in both studies, although the difference between treatment groups was not significant at this time in either study. However, by 60 days post-injection, the mean pain score has continued to fall in the BTX-A treatment groups, compared with a waning of the steroid therapeutic activity in the controls. The net effect was a highly significant difference between the two treatments in both the MPS (P <0.0001) and TH (P <0.0005) studies. No major adverse events were reported. In conclusion, BTX-A produces a more prolonged pain relief than methylprednisolone in patients suffering from MPS or TH.

AB - Myofascial pain syndrome (MPS) is characterised by acute and specific pain affecting the piriformis, iliopsoas or scalenus anterior muscles. Tension-type headache (TH) is a common pathological condition, which can be chronic or episodic. Based on its muscle-relaxant properties, botulinum toxin type A (BTX-A) has demonstrated efficacy in a variety of conditions involving dysregulated muscle contractions. Patients with MPS (n = 40) or TH (n = 20) were recruited to two randomised, single-blind studies, respectively. Each patient received either BTX-A or methylprednisolone, injected into the affected muscles after administration of a local anaesthetic. Pain was assessed at baseline, and 30 and 60 days post-treatment using a standard visual analogue scale. At 30 days post-injection, the mean pain score in all treatment groups was reduced compared with baseline in both studies, although the difference between treatment groups was not significant at this time in either study. However, by 60 days post-injection, the mean pain score has continued to fall in the BTX-A treatment groups, compared with a waning of the steroid therapeutic activity in the controls. The net effect was a highly significant difference between the two treatments in both the MPS (P <0.0001) and TH (P <0.0005) studies. No major adverse events were reported. In conclusion, BTX-A produces a more prolonged pain relief than methylprednisolone in patients suffering from MPS or TH.

KW - Botulinum toxin

KW - Muscle relaxant

KW - Myofascial pain syndrome

KW - Pain

KW - Tension-type headache

UR - http://www.scopus.com/inward/record.url?scp=0033373323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033373323&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033373323

VL - 6

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - SUPPL. 4

ER -